Another case of generalized bullous fixed drug eruption following an adenoviral vector-based COVID-19 vaccine (ChAdOx1 nCov-19).

Ben Salem, C; Khelif, A; Sahnoun, D; Ghariani, N; Sriha, B; Denguezli, M

Ben Salem, C; Khelif, A; Sahnoun, D; Ghariani, N; Sriha, B; Denguezli, M.

Ben Salem C; Clinical Pharmacology, Pharmacovigilance Center of Sousse, University of Sousse, Sousse, Tunisia.
Khelif A; Dermatology, Farhat Hached Hospital, University of Sousse, Sousse, Tunisia.
Sahnoun D; Clinical Pharmacology, Pharmacovigilance Center of Sousse, University of Sousse, Sousse, Tunisia.
Ghariani N; Dermatology, Farhat Hached Hospital, University of Sousse, Sousse, Tunisia.
Sriha B; Pathology, Farhat Hached Hospital, University of Sousse, Sousse, Tunisia.
Denguezli M; Dermatology, Farhat Hached Hospital, University of Sousse, Sousse, Tunisia.

J Eur Acad Dermatol Venereol ; 36(7): e516-e517, 2022 07.

Article in English | MEDLINE | ID: covidwho-1741442

Subject(s)

COVID-19; ChAdOx1 nCoV-19; Drug Eruptions; Adenoviridae; COVID-19/prevention & control; ChAdOx1 nCoV-19/adverse effects; Drug Eruptions/etiology; Humans

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Drug Eruptions / COVID-19 / ChAdOx1 nCoV-19 Type of study: Case report / Observational study Topics: Vaccines Limits: Humans Language: English Journal: J Eur Acad Dermatol Venereol Journal subject: Dermatology / Sexually Transmitted Diseases Year: 2022 Document Type: Article Affiliation country: Jdv.18059

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google